

**Drug Utilization Review (DUR) Meeting Minutes**  
**June 4, 2012**

**Members Present:** Norman Byers, John Savageau, Russ Sobotta, Cheryl Huber, Greg Pfister, Tanya Schmidt, Carrie Sorenson, Leann Ness, Carlotta McCleary, David Clinkenbeard, Steve Irsfeld

**Members Absent:** Kim Krohn, James Carlson, Jeffrey Hostetter, Todd Twogood

**Medicaid Pharmacy Department:** Brendan Joyce, Gary Betting

**HID Staff Present:** Candace Rieth

Chair, G. Pfister called the meeting to order at 1:00 pm. Chair, G. Pfister asked for a motion to approve the minutes from the March meeting. N. Byers moved that the minutes be approved and C. Huber seconded the motion. Chair, G. Pfister called for a voice vote to approve the minutes. The motion passed with no audible dissent.

**Budget Update**

B. Joyce informed the board members that the spend to pharmacies is within pennies of what was projected. Currently, the rebate dollars are fairly significant although the 100% federal match for line extension drug rebates has not been taken out to give the department a net-net total.

**Lorzone Second Review**

A motion and second were made at the March meeting to place Lorzone on prior authorization. The topic was brought up for a second review. There was no public comment. After discussion, Chair, G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent.

**Provigil Second Review**

A motion and second were made at the March meeting to place Provigil on prior authorization. The topic was brought up for a second review. There was no public comment. Chair, G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent.

**Kapvay Second Review**

A motion and second were made at the March meeting to place Kapvay on prior authorization. The topic was brought up for a second review. There was no public comment. Chair, G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent.

**Dexpak/Zemapak Second Review**

A motion and second were made at the March meeting to place Dexpak and Zemapak on prior authorization. The topic was brought up for a second review. There was no public comment. Chair, G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent.

**Xifaxan Second Review**

A motion and second were made at the March meeting to place Xifaxan on prior authorization. The topic was brought up for a second review. There was no public comment. Chair, G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent.

**Vanos Second Review**

A motion and second were made at the March meeting to place Vanos on prior authorization. The topic was brought up for a second review. There was no public comment. Chair, G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent.

### **Yearly PA Review**

The Board reviews products annually that have previously been placed on prior authorization. This allows the Board a chance to update the prior authorization forms and criteria. Sedative/Hypnotics, Quaalun, ACE-I/ARBs/Renin Inhibitors, Synagis, GH/IGF1, and Triptans were reviewed. No changes were made to the forms and criteria.

### **Topical Corticosteroid Review**

B. Joyce reviewed topical corticosteroid information with the Board. There was no public comment. After discussion, N. Byers suggested a dermatologist be consulted. The consult information will be provided at a later date.

### **Kalydeco Review**

B. Joyce reviewed Kalydeco information with the Board. There was no public comment. After discussion, N. Byers made a motion to place Kalydeco on prior authorization for FDA approved indication and requiring a CF mutation test. J. Savageau seconded the motion. This topic will be brought up at the next meeting for finalization.

### **Kuvan Review**

B. Joyce reviewed Kuvan information with the Board. There was no public comment. After discussion, C. Huber made a motion to place Kuvan on prior authorization for FDA approved indication. C. Sorenson seconded the motion. This topic will be brought up at the next meeting for finalization.

### **Elaprase Review**

B. Joyce reviewed Elaprase information with the Board. There was no public comment. After discussion, N. Byers made a motion to place Elaprase on prior authorization. C. Sorenson seconded the motion. This topic will be brought up at the next meeting for finalization.

### **Rescue Inhaler Review**

Brendan discussed rescue inhaler over-utilization with the Board. There is a population of recipients taking rescue inhalers that are using >12 puffs a day. The state would like to get the Board's advice on this trend. A suggestion was made to send an educational letter, with a survey requesting diagnosis information, to prescribers of recipients over-utilizing rescue inhalers.

### **Criteria Recommendations**

The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and usually are consistent with new indications, new drugs added, new warnings, etc. These proposed criteria will be added to the current set of criteria, and will be used in future DUR cycles. C. Huber moved to approve the new criteria and N. Byers seconded the motion. Chair, G. Pfister called for a voice vote. The motion passed with no audible dissent.

The next DUR board meeting will be held September 17th, 2012 in Fargo. G. Pfister made a motion to adjourn the meeting. C. Sorenson seconded. The motion passed with no audible dissent. Chair G. Pfister adjourned the meeting at 2:00 pm.